The Role of Targeted Alpha Radionuclide Therapy in Modern Oncology
Targeted Alpha Radionuclide Therapy precisely delivers potent alpha particles to tumors, maximising efficacy while sparing healthy tissues.
Targeted Alpha Radionuclide Therapy precisely delivers potent alpha particles to tumors, maximising efficacy while sparing healthy tissues.
Iodine-131 ICF01012, targeting melanin receptors, shows promise in the fight against metastasised melanomas, heralding a new era in treatment.
Iodine-131 chTNT, aiming to revolutionise oncology, shows promise in targeting and eradicating tumour cells with precision.
Iodine-131 CAM-H2 heralds a new era in oncology, offering hope through precise targeting of HER2-expressing cancers with minimal side effects.
Iodine-131 BA52, a melanin-binding therapeutic, offers new hope for patients with melanin-positive malignant melanomas.
Targeting Blood Cancers: The Role of Iodine-131 Apamistamab in Revolutionising Treatment for AML and Beyond.
World Theranostics Day honours Dr. Hertz’s groundbreaking radioiodine therapy, transforming disease treatment globally since 1941.
Iodine-131 Monoclonal Antibody 81C6 specifically targets glioma cells by honing in on the tenascin protein.
Holmium-166 Phytate, initially developed for chronic synovitis, has shown significant promise in phase I/II clinical trials.
Holmium-166 Chitosan, a groundbreaking radiopharmaceutical, offers new hope in treating hepatocellular carcinoma with targeted therapy.
Holmium-166 microspheres, by delivering localized radiation, significantly enhance the therapeutic approach to inoperable liver cancer treatment.
Copper-67 SARTATE emerges as a groundbreaking radiopharmaceutical in targeted cancer therapy, showcasing promising clinical trial results.
Copper-67 SARbisPSMA offers new hope in targeting and treating prostate cancer with precision and effectiveness.
Copper-64 Diasparagine offers a promising breakthrough in targeting and treating aggressive brain tumours like glioblastoma.
213Bi-Lintuzumab demonstrated efficacy in AML treatment, offering a targeted approach with manageable side effects, yet development paused.
213Bi-DOTATOC offers potent, targeted alpha therapy for tumours, advancing treatment with precision and reduced systemic toxicity.
211At-MX35-F(ab’)2 shows promise in treating ovarian cancer through targeted therapy in ongoing clinical trials.
Theragnomics melds theranostics and radiomics, promising targeted cancer therapies with improved outcomes through precision diagnostics and treatment adaptation.
The innovative 211At-MABG targets rare tumours like malignant pheochromocytoma and paragangliomas, promising a new era in treatment.
Radiotheranostics merges diagnostics and therapy, offering targeted cancer treatment amidst challenges like high costs and need for specialised facilities.
Thorium-227 emerges in nuclear medicine, revolutionizing cancer treatment through precise, effective radiotheranostic and therapeutic applications.
Neuroblastoma Targeting Agents offer innovative diagnostic and therapeutic options, revolutionizing treatment with precise targeting and efficacy.
Technetium-99m and Radium-223 are pivotal in managing bone metastases, enhancing both diagnostic accuracy and therapeutic efficacy.
Gallium-68 and Lutetium-177 labelled Girentuximab mark a breakthrough in diagnosing and treating hepatocellular carcinoma.
Utilising CXCR4 targeting agents with labelled ligands marks a breakthrough in treating haematological malignancies effectively.
Folate Receptor Targeting Agents revolutionise cancer diagnosis and treatment with Fluorine-18 and Rhenium-188 labelling.
Estrogen receptor targeting agents, including Fluorine-18 and Iodine-131 analogues, revolutionise breast cancer diagnostics, therapeutics, and personalised patient management.
FAPI revolutionises oncology with precise Gallium-68 diagnostics and targeted Lutetium-177 therapy for cancer.
Somatostatin Receptor Targeting Agents offer groundbreaking diagnostic and therapeutic solutions for neuroendocrine tumour management and care.
PSMA targeting agents revolutionise prostate cancer care with precise diagnostics and targeted therapeutic approaches.